Press Releases

Year

February 11, 2022

4D Molecular Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

EMERYVILLE, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in the 11 th Annual SVB Leerink Global

February 9, 2022

4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium

Following discontinuation of ERT, AGA activity was stable at 14-fold mean normal level through week 37 (Patient 1) and stable at 10-fold mean normal levels through week 20 (Patient 3) Preliminary clinical data suggest encouraging improvement in cardiac imaging endpoints, specifically native T1 for

February 2, 2022

4D Molecular Therapeutics to Present Updated Clinical Data with 4D-310 in Fabry Disease Patients in Platform Presentation at the 18th Annual WORLDSymposium

EMERYVILLE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced updated interim clinical data from the on-going 4D-310 Phase 1/2 trial in patients

January 10, 2022

4D Molecular Therapeutics Announces FDA Fast Track Designation Granted to 4D-125 for the Treatment of X-linked Retinitis Pigmentosa

EMERYVILLE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation

January 6, 2022

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-150, a Dual-Transgene Intravitreal Gene Therapy for Patients with wet AMD

EMERYVILLE, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT) (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the first patient has been dosed in the Phase 1/2 clinical trial

November 23, 2021

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference

EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in a fireside chat at the Evercore ISI HealthCONx

November 10, 2021

4D Molecular Therapeutics Reports Financial Results for the Third Quarter of 2021 and Provides Operational Highlights

EMERYVILLE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced financial results for the third quarter of 2021 and provided operational

October 28, 2021

4D Molecular Therapeutics Announces Pricing of Public Offering of Common Stock

EMERYVILLE, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it priced an underwritten public offering of 4,750,000 shares of

October 26, 2021

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

EMERYVILLE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced today that it has commenced an underwritten public offering of 4,500,000 shares of

October 25, 2021

4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia

- First-ever clinical activity data reported on 4D-310 Fabry disease product candidate utilizing the proprietary C102 targeted and evolved vector invented through Therapeutic Vector Evolution - AGA enzyme activity was within, or significantly above, the normal range in all three patients (up to

Pagination

First page
Previous page
…
Page 5
Page 6
Current page 7
Page 8
Page 9
…
Next page
Last page

About 4DMT

Navigation

Location